Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Mersana Therapeutics, Inc. (NASDAQ:MRSN) has been given a consensus rating of “Moderate Buy” by the eight ratings firms that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $5.57.

A number of equities research analysts recently commented on the company. Wedbush reaffirmed an “outperform” rating and set a $4.00 target price (down previously from $7.00) on shares of Mersana Therapeutics in a report on Friday, January 10th. Citigroup began coverage on Mersana Therapeutics in a research report on Friday, November 15th. They issued a “buy” rating and a $5.00 target price for the company.

Mersana Therapeutics Stock Performance

Shares of Mersana Therapeutics stock opened at $0.55 on Wednesday. The company has a market capitalization of $67.93 million, a PE ratio of -0.90 and a beta of 1.43. The stock’s fifty day moving average is $1.74 and its two-hundred day moving average is $1.82. Mersana Therapeutics has a 52 week low of $0.55 and a 52 week high of $6.28. The company has a quick ratio of 2.35, a current ratio of 2.35 and a debt-to-equity ratio of 13.35.

Mersana Therapeutics (NASDAQ:MRSN) last released its quarterly earnings results on Wednesday, November 13th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.08. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%. The business had revenue of $12.60 million during the quarter, compared to analyst estimates of $7.53 million. During the same period in the prior year, the firm posted ($0.35) earnings per share. The company’s quarterly revenue was up 63.6% on a year-over-year basis. As a group, analysts expect that Mersana Therapeutics will post -0.61 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of MRSN. US Bancorp DE purchased a new position in shares of Mersana Therapeutics during the 3rd quarter worth approximately $31,000. Dynamic Technology Lab Private Ltd acquired a new position in Mersana Therapeutics in the 3rd quarter valued at about $34,000. Intech Investment Management LLC acquired a new stake in Mersana Therapeutics during the third quarter worth approximately $52,000. Quarry LP purchased a new position in Mersana Therapeutics during the third quarter worth about $57,000. Finally, Avanza Fonder AB purchased a new stake in Mersana Therapeutics in the fourth quarter valued at approximately $81,000. 93.92% of the stock is currently owned by hedge funds and other institutional investors.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.